Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vijaykumar Chennupati

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Immunity|January 13, 2019
Intratumoral Tcf1<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup> T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade ImmunotherapyImran Siddiqui, Karin Schaeuble, Vijaykumar Chennupati, et al.
The Journal of Clinical Investigation|February 7, 2018
Ribonuclease inhibitor 1 regulates erythropoiesis by controlling GATA1 translationVijaykumar Chennupati, Diogo Ft Veiga, Kendle M Maslowski, et al.
Mabs|August 29, 2024
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releaseJohn S Schardt, Even Walseng, Kim Le, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Immunity|January 13, 2019
Intratumoral Tcf1<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup> T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade ImmunotherapyImran Siddiqui, Karin Schaeuble, Vijaykumar Chennupati, et al.
The Journal of Clinical Investigation|February 7, 2018
Ribonuclease inhibitor 1 regulates erythropoiesis by controlling GATA1 translationVijaykumar Chennupati, Diogo Ft Veiga, Kendle M Maslowski, et al.
Mabs|August 29, 2024
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releaseJohn S Schardt, Even Walseng, Kim Le, et al.
Pageof 3